A Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction.

Trial Profile

A Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs Belinostat (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Oct 2017 Status changed from recruiting to completed.
    • 08 Mar 2017 Planned primary completion date changed from 4 Mar 2017 to 8 Jan 2018.
    • 17 Feb 2016 Planned End Date changed from 1 Mar 2016 to 1 Mar 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top